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Objective: To describe the item-selection and item-reduction for the Lung Function 
Questionnaire (LFQ), being developed to help clinicians identify patients appropriate for diag-
nostic evaluation for chronic obstructive pulmonary disease (COPD) using spirometry. 
Methods: Item selection and reduction were based on information from 387 40-year-old 
respondents to the third National Health and Nutrition Examination Survey who had self-reported 
chronic bronchitis. Item reduction involved stepwise logistic regression. The accuracy of the final 
subset of items for identifying individuals with airflow obstruction (forced expiratory volume 
in one second/forced vital capacity 0.70) versus those without it was assessed with receiver 
operating characteristic analysis. Content and face validity were assessed using focus groups 
of primary care physicians (n = 16) and interviews with COPD patients (n = 16).
Results: The model with all five items (age; smoking history; the presence of wheeze, dyspnea, 
and phlegm) compared with models with combinations of fewer items had the highest classifica-
tion accuracy (area under the curve [AUC] = 0.720) with sensitivity and specificity of 73.2% 
and 58.2%, respectively. The presence of three or more factors yielded the highest AUC, a result 
suggesting that three or more affirmative answers is the most appropriate criterion indicating 
presence of airflow obstruction.
Conclusions: The five-item LFQ retained sufficient accuracy, sensitivity, and specificity in 
identifying individuals with COPD for further validation testing.
Keywords: spirometry, chronic obstructive pulmonary disease, respiratory disease, chronic 
bronchitis, diagnosis, screening
Introduction
Chronic obstructive pulmonary disease (COPD) affects approximately 12 million 
adults in the United States, where it causes approximately 1.5 million emergency 
department (ED) visits, 726,000 hospitalizations, and 119,000 deaths annually.1 COPD 
is manifested by cough, sputum production, and breathlessness associated with air-
flow obstruction.2 Deterioration in lung function impairs patients’ general health and 
quality of life and eventually leads to respiratory failure and premature death. Until 
recently, the progression of COPD was viewed as being inexorable and the disease as 
being refractory to therapeutic intervention. Contradicting this view, a convergence 
of evidence suggests that, although lung tissue damage in COPD appears to be per-
manent, the course of the disease can be altered through measures such as smoking 
cessation, pulmonary rehabilitation, and use of pharmacotherapy.3–6 Data showing that 
symptoms and frequency of exacerbations can be reduced and exercise capacity and 
health status can be improved with intervention have shifted the paradigm in COPD International Journal of COPD 2010:5 
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management such that the disease is now viewed as being 
preventable and treatable.4,5
In this new paradigm, early identification of COPD and 
aggressive approaches to treatment are regarded as being 
integral to optimizing outcomes.6 Primary care physicians, 
who are thought to provide care for the majority of patients 
with early or mild COPD, are crucial in efforts to prevent 
COPD and to diagnose it early.3 However, data suggest that 
COPD is underdiagnosed in primary care as it is in other 
health care settings. For example, in a recent study conducted 
in the primary care setting, 182 of 1960 patients (9.3%) were 
found to meet diagnostic criteria for COPD, but only 19% 
of those meeting the diagnostic criteria had been diagnosed 
and treated.7 Diagnosis of COPD is complicated by the 
fact that, during its initial, often prolonged stage, COPD 
symptoms can be confused with aging, de-conditioning, 
or symptoms of other chronic conditions and therefore not 
recognized as a respiratory issue by patients or their health 
care professionals.3
Diagnosis of COPD is based on objective evidence of 
airflow limitation, usually defined as a postbronchodila-
tor forced expiratory volume in one second/forced vital 
capacity ratio (FEV1/FVC)  0.70 associated with risk 
factors such as smoking and/or symptoms of chronic 
sputum production, wheezing, and dyspnea.2 If detection 
of COPD is to be improved in primary care, screening tools 
for detection of early symptomatic COPD prior to the onset 
of disabling symptoms are needed. Although necessary 
for diagnosing COPD, spirometry is not recommended as 
a screening tool as its benefits do not outweigh potential 
harms according to a recent evidence-based review con-
ducted for the US Preventive Services Task Force.8 Since 
that review, one study has suggested that giving patients 
their lung age rather than just the FEV1 from spirometry 
testing doubled smoking quit rates.9 This result suggests a 
possible benefit of spirometry screening beyond the diag-
nosis of COPD. Further evaluation is necessary before the 
possible smoking-cessation benefit can justify widespread 
spirometry screening.
Until then, a screening tool for detection of people 
appropriate for spirometry evaluation should be brief, self-
completed, and easy to administer and score and must have 
high sensitivity and reasonable specificity for spirometry-
confirmed airflow obstruction. This paper describes the 
item-selection and item-reduction phases of the development 
of the Lung Function Questionnaire (LFQ), designed as a 
patient-completed screening tool that can be used efficiently 
in primary care settings to detect those appropriate for 
spirometry testing for airflow obstruction. Future studies 
will be required to validate the use of the LFQ in primary 
care practice.
Methods
The initial development of the LFQ occurred in two phases: 
1) an empirical item-selection and item-reduction phase dur-
ing which candidate questionnaire items were identified and 
their accuracy evaluated and 2) a qualitative phase to assess 
for content validity and face validity.
empirical phase: Item evaluation  
and reduction
sample
The study sample was a subset of the third National Health 
and Nutrition Examination Survey (NHANES III), a US 
population-based survey conducted from 1988 to 1994.10 The 
survey involved 33,994 respondents who were interviewed in 
their homes and then invited to a mobile examination center 
for a medical examination that included a physical examina-
tion, completion of several questionnaires or interviews, and 
tests and procedures including spirometry. To be included in 
the current study, respondents had to be at least 40 years old 
and to have a self-reported diagnosis of chronic bronchitis 
(CB), defined as an affirmative answer to the question, “Has 
a doctor ever told you that you had chronic bronchitis?” 
No questions on self-reported COPD or emphysema were 
included in NHANES III.
Patients with airflow obstruction, defined as prebron-
chodilator FEV1/FVC  0.70, were compared with patients 
without airflow obstruction with respect to age; gender; 
smoking history; and presence of phlegm, dyspnea, wheeze, 
and cough. The groups were compared using the chi-square 
test for categorical variables and the t-test for continuous 
variables.
Item reduction
The first phase of the study involved evaluating eight can-
didate items for potential inclusion in the LFQ. The eight 
candidate items, which were based on known risk factors 
for airflow obstruction, were assessed for accuracy in cor-
rectly identifying individuals with airflow obstruction in the 
NHANES III sample. Selection of these items was based 
on literature reviews and clinical input. Stepwise selection 
procedures were conducted for eight base models based on 
varying cutoffs for the candidate items (Table 1). In each base 
model, the dependent variable was the presence of airflow 
obstruction; and the independent variables were age, body International Journal of COPD 2010:5 
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mass index, cough, phlegm, dyspnea, wheeze1, wheeze2, 
and smoke (Table 1 for variable definitions as captured in 
NHANES). Cough, phlegm, dyspnea, wheeze1, and wheeze2 
were coded as binary variables (1 = yes; 0 = no). Smoke was 
coded as 1 if the respondent indicated smoking for at least 
20 years; otherwise a value of zero was used. For each of the 
remaining two independent variables, two different cutpoints 
were used (Table 1). The base models were evaluated for 
classification accuracy in terms of sensitivity, specificity, and 
area under the receiver operating characteristic (ROC) curve 
(using probability cutoff of 0.500).
Next, stepwise logistic regression procedures were used 
to reduce the number of items and to identify the items most 
predictive of airflow obstruction (item reduction). In gen-
eral, item choice was based on the results obtained with the 
base models, clinical relevance, and ease of administration 
of the questionnaire. The classification accuracy of eight 
reduced models obtained from the stepwise procedure was 
compared with that of the base models in terms of sensitivity, 
specificity, and area under the ROC curve (probability 
cutoff, 0.500).
evaluation of accuracy
The accuracy of the final (reduced) subset of items identified 
for inclusion in the LFQ was assessed using ROC analysis. 
The area under the ROC curve (AUC), which was obtained 
for all combinations of the candidate items, was used as 
the measure of accuracy. AUC values  0.7 were consid-
ered to reflect acceptable accuracy for detecting airflow 
obstruction.
sensitivity analysis
As a sensitivity analysis we re-defined the dependent vari-
able to reflect GOLD stage II disease ie, FEV1/FVC fixed 
ratio  0.7 and FEV1 80% predicted (prebronchodilator) 
for those aged 65 and older. Subjects aged less than 65 
years were classified as obstructed if FEV1/FVC  0.7. 
Logistic regression models were used to identify items from 
the questionnaire most predictive of obstruction; screen-
ing accuracy was also tested using ROC curve analyses. 
Additionally, a general population comprising individuals 
aged 40 years and older was used in a sensitivity analysis 
to explore performance of the candidate pool of items 
and whether the items selected would change (results not 
shown). This additional analysis was done to ensure that 
the LFQ items did not restrict properties studied to only a 
sample of patients with symptoms consistent with chronic 
bronchitis.
Preliminary scoring of LFQ
To examine the minimum number of items associated with 
best accuracy, the accuracy of the model was examined 
according to different cutpoints of a summed scale derived 
from the subset of variables included in the best perform-
ing model. The predictor model with the highest AUC was 
considered to reflect the minimum score of the LFQ that 
most accurately predicts airflow obstruction. (Scoring will 
be tested further in the subsequent validation study, which 
will include testing of five-point response options for LFQ 
questions).
Qualitative phase: Content validity  
and face validity
The qualitative phase involved physician focus groups 
and one-on-one patient interviews to test further the 
Table  Base models explored as stepwise regressions and candidate 
items included in analysis
Predictors of obstruction
1 Age (50+ years), BMI (18 kg/m2), cough, phlegm, dypsnea,  
wheeze1, smoke (20 years)
2 Age (60+ years), BMI (18 kg/m2), cough, phlegm, dypsnea,  
wheeze1, smoke (20 years)
3 Age (50+ years), BMI (25 kg/m2), cough, phlegm, dypsnea,  
wheeze1, smoke (20 years)
4 Age (60+ years), BMI (25 kg/m2), cough, phlegm, dypsnea,  
wheeze1, smoke (20 years)
5 Age (50+ years), BMI (18 kg/m2), cough, phlegm, dypsnea,  
wheeze2, smoke (20 years)
6 Age (60+ years), BMI (18 kg/m2), cough, phlegm, dypsnea,  
wheeze2, smoke (20 years)
7 Age (50+ years), BMI (25 kg/m2), cough, phlegm, dypsnea,  
wheeze2, smoke (20 years)
8 Age (60+ years), BMI (25 kg/m2), cough, phlegm, dypsnea,  
wheeze1, smoke (20 years)
Notes: Age was a categorical variable, and different age cutoffs were explored. 
An age cutoff of 50 years and older was the most predictive category.   Therefore, the 
age variable in this analysis was age 50 years (Yes/no). Body mass index (BMI) was 
a continuous variable, and two cutoffs were explored (18 kg/m2 and 25 kg/m2); 
Cough was defined in NHANES as “Do you usually cough on most days for three 
consecutive months or more during the year?” (Yes/No).   Wheeze1 was defined 
in NHANES as “Have you had wheezing or whistling in your chest at any time in 
the past 12 months?” (Yes/No). Wheeze2 was defined in NHANES as “Apart from 
when you have a cold, does your chest ever sound wheezy or whistling?” (Yes/no). 
Dyspnea was originally captured in NHANES as “Are you troubled by shortness of 
breath when hurrying on level ground or walking up a slight hill?” (Yes/no). Phlegm 
was originally defined in NHANES as “Do you bring up phlegm on most days for 
three consecutive months or more during the year?” (Yes/No). Smoke was defined 
in NHANES as “For approximately how many years have you smoked this amount?” 
(a question was preceded by “About how many cigarettes do you smoke per day”). 
For the purposes of this analysis, smoking for 20 years was used as the frame of 
reference for the question.International Journal of COPD 2010:5 
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face and content validity (clinical relevance) of the questions 
and response options. The physician focus groups comprised 
16 primary care physicians (who were eligible to participate 
if they had treated at least 10 patients with CB per month 
and had a minimum of three years postresidency experience 
in practice) who were asked to review the screener and to 
provide feedback in focus groups conducted during February 
and March 2007 in Philadelphia, Pennsylvania. The focus 
groups were conducted by experienced moderators who used 
structured discussion guides.
After incorporating feedback from the focus groups, 
the face validity of the resulting items was evaluated during 
two rounds of cognitive one-on-one interviews held during 
March 2007 in Collegeville, Pennsylvania, with 16 patients 
(eight per round). Patients were aged at least 40 years with 
a confirmed physician diagnosis of COPD or emphysema 
(round 1 of interviews) or to have a diagnosis of CB or self-
reported productive, chronic cough on most days for at least 
three months of the year within the last two years (round 2 of 
interviews). One-on-one interviews were conducted using a 
standard “think-aloud” procedure and directed probes about 
the draft screener title, directions, and items while describing 
their thought processes aloud until saturation of information 
was reached.
Results
empirical phase: Item evaluation  
and reduction
sample
Table 2 summarizes characteristics of the study sample 
for item evaluation and reduction. The sample included 
387 patients, 51% of whom had airflow obstruction. Although 
all in the study sample had a self-reported diagnosis of CB, 
only 32% reported cough symptoms. Patients with airflow 
obstruction by spirometry compared with those without air-
flow obstruction were older; more likely to be male; to have 
smoked at least 20 years; and to have symptoms of phlegm, 
dyspnea, wheeze, and cough.
Item reduction
In stepwise selection procedures on the eight base models, 
AUC values ranged from 0.775 to 0.811 across models. 
Ranges for sensitivity and specificity were 57.8% to 64.9% 
and 68.5% to 83.8%, respectively. The following vari-
ables were statistically significant (0.05) across models: 
age, dyspnea, wheeze1, and smoke. Although body mass 
index (BMI) (specifically, BMI  25) was also statisti-
cally significant in stepwise analyses, it was only weakly 
related to prebronchodilator FEV1/FVC in linear regression 
analyses. This variable was eliminated from consideration 
for the reduced subset because of low discriminatory 
power and the difficulty of easily and reliably assessing it 
in a patient-reported questionnaire (as calculation involved 
computation). Wheeze2 was chosen in favor of wheeze1 
for inclusion in the reduced subset of potential LFQ items 
based on clinician advice suggesting that wheeze2 was the 
more clinically useful and specific item. Also, AUC values 
of models including wheeze2 instead of wheeze1 did not 
appreciably differ. Phlegm was not identified in any of the 
regression models. However, because of its clinical impor-
tance, phlegm was included in the questionnaire. Final items 
included in the questionnaire were age, dyspnea, wheeze2, 
smoke, and phlegm.
Table  Demographics and clinical characteristics
All patients Prebronchodilator 
FEV/FVC
P-value*
0.70 0.70
n (%) 387 (100.0) 189 (49.0) 198 (51.0)
Age (mean years) 61.4 56.8 65.7 0.0001
Age group (%) 0.0001
  40–49 22.0 33.3 11.1
  50–59 20.2 22.8 17.7
  60–69 28.4 27.0 29.8
  70+ 29.5 16.9 41.4
Male (%) 46.8 38.1 55.1 0.0008
smoked for  
20 years or  
more (%)
64.6 56.1 72.7 0.0006
Pack-years (mean) 35.6 26.2 44.6 0.0001
Pack-years (%) 0.0001
  10 30.2 36.0 24.7
  10–20 14.7 20.1 9.6
  20–30 11.6 13.8 9.6
  30–40 10.3 10.1 10.6
  40 33.1 20.1 45.5
Phlegm (%) 30.0 22.2 37.4 0.0011
Dyspnea (%) 65.6 53.4 77.3 0.0001
Wheeze (%) 49.9 42.3 57.1 0.0037
Cough (%) 32.0 26.5 37.4 0.0214
FeV1/FVC (mean) 67.0 77.6 56.9 0.0001
Notes: *P values were calculated using chi-square tests for categorical variables and 
t-tests for continuous variables.
Abbreviations: FeV1, forced expiratory volume in one second; FVC, forced vital 
capacity.International Journal of COPD 2010:5 
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Table  Results of multivariate logistic regression of the five Lung 
Function Questionnaire items
Odds ratio estimates
Item Point estimate 9% CI
Age
  Less than 50 years Reference
  50 years and older 3.322 1.869–5.904
Wheeze
  no
  Yes 1.598 0.993–2.572
Dyspnea
  no
  Yes 1.996 1.218–3.272
Phlegm
  no
  Yes 1.548 0.950–2.523
Smoked for 0 years
  no
  Yes 1.806 1.133–2.878
Abbreviation: CI, confidence interval.
Accuracy of the reduced model  
and cutpoint analysis
Table 3 shows the odds ratios for presence of airflow 
obstruction from multivariate logistic regression of the 
reduced subset of five potential LFQ items. The five items 
differentiated patients with airflow obstruction from those 
without airflow obstruction in the NHANES III database. 
After controlling for wheezing, dyspnea, phlegm, and 
smoking, the odds of airflow obstruction for those aged 
50 years and older were more than three times the odds 
of airflow obstruction for those aged less than 50 years. 
Those who had smoked for at least 20 years were 1.8 times 
more likely to have airflow obstruction than those who had 
smoked for 0 to 19 years. Airflow obstruction was 1.5, 
2.0, and 1.5 times more likely to be present in those with 
wheeze, dyspnea, and phlegm, respectively, than in patients 
without these symptoms.
The model with all five items (variables) had the highest 
AUC (0.720) with sensitivity and specificity of 73.2% and 
58.2%, respectively. Figure 1 shows the ROC curve for the 
best model (ie, that with five items). The ROC curve describes 
the accuracy of a test regardless of the decision threshold. 
Each point in the ROC plot represents the combination of 
sensitivity and specificity values generated by a different 
decision threshold.
sensitivity analysis
Redefining the criteria for obstruction per the sensitivity 
analysis (SA) resulted in negligible changes in the overall 
results. Under the new definition, the accuracy of the LFQ 
(AUC = 0.709) decreased slightly, a result that shows that 
the items are not appreciably affected by the “aging lung” 
phenomenon. Also, in another SA using a base population 
of individuals aged more than 40 years, the performance 
of LFQ questions was very similar to performance in 
the CB population (data not reported). This finding sug-
gests that the LFQ captures concepts related to airflow 
obstruction.
Table 4 shows the AUCs for logistic regressions using 
dichotomized predictors derived from the LFQ summed 
score. A score 3 (regardless of the combination of ques-
tions) on the LFQ scale yielded the highest AUC and suggests 
a risk of airflow obstruction. (Scoring will be tested further 
in a subsequent validation study for the LFQ).
Qualitative phase: Content validity  
and face validity
Table 5 shows the LFQ items identified during the empiri-
cal phase of development and the changes made to these 
items in response to qualitative input from physicians and 
patients.
Content validity
The 16 physicians who participated in focus groups to 
assess content validity of the final set of five LFQ items had 
been in practice a mean 13.9 years (range 3.5 to 30 years) 
and treated an average of 59.4 patients (range 20 to 150) 
with CB per month. All physicians practiced in the primary 
care setting (10 family practice, five internal medicine, one 
general practice).
Physicians’ review of the draft questionnaire resulted in 
modification of the directions for completion of the LFQ to 
enhance clarity as well as revision of the items on shortness 
of breath and phlegm (which physicians suggested be instead 
termed mucus) to enhance understanding (Table 5).
Face validity
The majority of the 16 patients who participated in one-
on-one cognitive interviews to assess face validity of the LFQ 
were female (61%). Patients indicated that items and concepts 
in LFQ were relevant to their disease and symptoms. Based on 
patient feedback, changes were made to the order of the items 
until patients brought up no new information. When the ques-
tions regarding smoking were presented first, respondents International Journal of COPD 2010:5 
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Table  Preliminary scoring for the Lung Function Questionnaire
Cutpoint AUC Probability  
level
Sensitivity Specificity % of correct 
classification
1 0.537 0.500 99.5 7.9 54.8
2 0.576 0.500 92.9 22.2 58.4
3 0.651 0.500 77.8 52.4 65.4
4 0.637 0.500 47.0 80.4 63.3
5 0.562 0.500 16.2 96.3 55.3
Abbreviation: AUC, area under the curve.
indicated they felt it was a “smoking questionnaire” and felt 
threatened/attacked by it. Re-ordering of the same items 
addressed this concern (Table 5). Other significant changes 
based on patient input included simplification of the instruc-
tions and development of more precise wording for the items 
and response options.
Discussion
Previously regarded as an inexorably progressive disease 
that is refractory to treatment, COPD is now understood to 
be treatable through measures such as smoking cessation, 
pulmonary rehabilitation, and use of pharmacotherapy.3–6 
Early identification of COPD is crucial to treatment efforts. 
Because spirometry is not practical as a screening tool in 
many healthcare settings,8 alternatives to spirometry are 
needed to screen patients for COPD. In this study, a set of 
items that accurately identifies patients with spirometry-
based airflow obstruction, the primary manifestation of 
COPD, was identified for potential inclusion in the LFQ. 
Items related to age; occurrence of wheezing, phlegm, and 
* * * * * * * * * * * * * * * *
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Figure  Receiver operating characteristics for the five Lung Function Questionnaire items.
Abbreviation:  AUC, area under the curve.International Journal of COPD 2010:5 7
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dyspnea; and smoking history were identified for inclusion 
in the LFQ based on the statistical analysis, expert advice 
regarding the clinical relevance of the candidate items, and 
ease of administration of items. The final set of items in this 
initial development of the LFQ achieved a classification 
accuracy of 0.72, a value that reflects fair accuracy. The 
balance of sensitivity (73.2%) and specificity (58.2%) was 
good as a relatively greater focus on sensitivity is desirable 
in noninvasive screening tools such at the LFQ. It is pertinent 
to recognize that lack of higher specificity does suggest some 
practical implications for the LFQ in this current form. This 
implies higher number of false positives and therefore has a 
practical burden of time and cost for physicians.8 It should 
be recognized that these characteristics constitute only pre-
liminary exploration of characteristics of these questions as 
posed in NHANES III survey (yes/no format). A subsequent 
validation study will examine these properties in an inde-
pendent sample of respondents in a primary care practice. 
This validation study will further refine the properties of the 
LFQ such that this burden of false positives is minimized. In 
previous research, an initially promising COPD diagnostic 
questionnaire based on airflow obstruction was found not 
to be externally valid in a high-risk population comprising 
middle-aged current smokers,11 a finding that highlights the 
importance of thorough external validation studies.
The sample for the empirical phase of the study involved 
individuals at least 40 years old with a self-reported diagno-
sis of CB who had participated in the US population-based 
NHANES III survey.10 This sample has been previously used 
to describe the epidemiology of airflow obstruction in the 
general population12 and to assess the usefulness of screener 
questions to identify those having airflow obstruction.13 The 
representativeness of the sample suggests that the findings of 
the current study are widely generalizable. Individuals aged 
40 years or older were chosen for study because they are the 
target population for COPD screening; COPD is rare in those 
younger than 40 years. This study included patients reporting 
chronic bronchitis to ensure item selection in an “at-risk” 
sample. Selecting an initial pool of items from a general 
population may not have illustrated characteristics that one 
that was more “at risk” for COPD would. In order to explore 
what impact this may have on the items, the same models 
were tested and regression procedures were performed on a 
general population taking away the restriction of chronic bron-
chitis. No appreciable impact on results or on items selected 
was found. Lung capacity is known to diminish with age.14 
Therefore, a classification scheme relying on FEV1/FVC  0.7 
across all age groups is likely to result in large false-positive 
rates among elderly respondents (aged 65 and older). To 
address this “aging lung” phenomenon, a separate analysis 
that redefined dependent variable of airflow obstruction as 
FEV1/FVC fixed ratio  0.7 and FEV1 80% predicted was 
conducted for individuals 65 years and older. The dependent 
variable for those under 65 years remained the same – that is, 
FEV1/FVC fixed ratio  0.7. Results (not shown) remained 
fairly consistent and final LFQ items remained unchanged. 
As discussed previously, the authors also examined whether 
these variables would perform in a similar fashion within a 
multivariate setting in a general NHANES population aged 
40 years and older regardless of chronic bronchitis diagnosis, 
Results were fairly similar and further strengthened the choice 
of the items from the primary analysis.
Evidence suggests that continuum-based scales have 
better psychometric properties than dichotomous Yes/No 
scales.15 In order to investigate this further, in addition to the 
Yes/No answer format used in the present study, questions 
Table  Lung Function Questionnaire items identified during the empirical phase (Version 1) and the revised Lung Function Questionnaire 
resulting from qualitative input from physicians and patients (Version 2)
Version  Version 
Do you currently smoke? Do you frequently cough up mucus?
how many years have you smoked? Does your chest often sound noisy (wheezy, whistling) when you breathe?
When smoking, about how many cigarettes were or are typically  
smoked each day?
Do you experience shortness of breath upon physical exertion (walking up 
a flight of stairs or walking up an incline without stopping to rest)?
Are you troubled by shortness of breath when hurrying on level  
ground or walking up a slight hill?
What is your age range?
Apart from when you have a cold, does your chest ever sound  
wheezy or whistling?
how many years have you smoked?
Do you bring up phlegm on most days for three consecutive  
months or more during the year?
When smoking, about how many cigarettes were or are typically smoked 
each day?
What is your age range? Do you currently smoke?International Journal of COPD 2010:5 
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with five-point Likert-type response scales were included 
in a subsequent validation study (the subject of a separate 
manuscript). The objective of the validation study is to further 
ascertain the screener’s psychometric properties, including 
screening accuracy, and to determine the performance of the 
Yes/No response options compared with a five-point scale.
The current research extends previous findings estab-
lishing the feasibility of using screening questionnaires to 
identify those at risk of airflow obstruction or COPD.13,16–22 
The LFQ is being developed to improve upon many COPD 
screening tools19,21,22 by being easy to self-administer, by 
not requiring interviewer administration or information 
from medical records, and by being broadly useful across 
patient types and settings rather than being targeted only to 
a particular population (eg, smokers). The LFQ demonstrated 
good content validity and face validity among physicians 
and patients during the qualitative phase of assessment. With 
these characteristics, the LFQ should be particularly appro-
priate for use in the primary care setting. The LFQ should 
also be useful as an initial screener in epidemiological stud-
ies, disease management programs, and clinical research. In 
ongoing research, the LFQ is being further validated among 
primary care providers and patients.
Several other screening tools for COPD have been 
explored.13,16–25 The LFQ is unique among existing tools in 
having demonstrated both content validity and face validity, 
which are critical to an instrument’s utility in clinical practice. 
Both patient input and physician input were integral in the 
establishment of face validity and content validity of the LFQ. 
The content of items was both driven and confirmed by 
patients and physicians. Furthermore, question and response 
options were refined based on patient and physician feedback 
in order to maximize their relevance to patients and to the 
disease of interest. Input from primary care clinicians was 
particularly useful in shaping the instrument to be practical 
for use in the target setting. Through a sequential process, 
items that were selected from NHANES using a statistical 
model were further refined by qualitative patient and physi-
cian input. Within the realms of instrument development, 
this follows accepted methodology. The qualitative step in no 
way precludes the screening properties of the LFQ obtained 
from the first step. The LFQ also differs from existing screen-
ing tools for COPD in the extent to which its psychometric 
properties and clinical utility are being refined in a sequential 
process. The study described herein is one of a program of 
studies designed to refine and validate the LFQ.
Many questionnaires have been developed using infor-
mation from specialty populations in the United States. The 
NHANES survey is a very large representative sample of US 
patients who are arguably comparable to primary care popula-
tions in the United States. The NHANES data were used to 
select questions for further validation studies. As lung function 
measurements were available in these patients, they seemed 
appropriate to consider as a group that had reported physician 
diagnosis of chronic bronchitis. Furthermore, patients with self-
reported chronic bronchitis were selected in order to be able 
to discern most relevant items predicting airflow obstruction. 
Also, because the majority of patients with early, undiagnosed 
COPD (the targets of this questionnaire) are passed off as having 
smoker’s cough or chronic bronchitis, the initial pool of ques-
tions was developed using this population. This sample was 
felt to provide more disease-specific inputs for further testing. 
While COPD is underdiagnosed in primary care, it is also likely 
incorrectly diagnosed without the use of spirometry in many 
practices. Therefore, this group is appropriate to include in the 
question selection. The entire process of item selection was also 
repeated using a general population aged 40 years and older to 
examine any changes in item selection as a sensitivity analysis. 
This analysis did not change the pool of items selected.
The LFQ is being developed to help health care profession-
als screen for obstructive lung disease manifested by prebron-
chodilator FEV1/FVC  0.70, a likely marker for COPD. As a 
screening tool, the LFQ can help health care providers identify 
patients in need of further evaluation for possible COPD but 
is not intended as a diagnostic tool. Patients whose LFQ score 
suggests the presence of airflow obstruction require clinical 
evaluation and spirometric assessment to assess for COPD.
This study should be interpreted in the context of the 
limitation that it was conducted in individuals who self-
reported a diagnosis of CB. While inclusion of only these 
patients was useful in profiling the performance of LFQ 
items in the target population, the performance of LFQ items 
in nonselected samples is also of interest. Additional valida-
tion studies are needed to assess the performance of LFQ 
items in community-based samples that include individuals 
without self-reported CB. Another limitation of this study 
is the use of prebronchodilator spirometry as a criterion 
measure. It is clinically accepted that postbronchodilator 
spirometry, after accounting for reversibility, may be a better 
measure of lung function than prebronchodilator spirometry. 
The use of prebronchodilator spirometry was dictated by the 
source of data for this study – the NHANES III survey. The 
NHANES III survey captured prebronchodilator spirometry, 
but not postbronchodilator spirometry. In subsequent valida-
tion studies of the LFQ, postbronchodilator spirometry will 
be used as a criterion measure. This change is not expected to International Journal of COPD 2010:5 9
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result in major changes in the characteristics or performance of 
the LFQ. Information around the recall period was not available 
for these questions (primarily because these questions within 
NHANES were captured in yes/no format). However, informa-
tion around recall period was addressed in patient cognitive 
interviews as well as physician focus groups. Feedback did not 
suggest that absence of recall was necessarily a handicap owing 
to simplicity of questions and concepts being explored.
In summary, the five-item LFQ can be used in the primary 
care setting as a patient-completed screening tool to identify 
patients with a high risk of airflow obstruction. The LFQ had 
adequate accuracy, sensitivity, and specificity in a sample 
comprising individuals with self-reported CB and had good 
content and face validity according to primary care physicians 
and patients. The LFQ is a good candidate tool to facilitate 
earlier recognition of COPD. Further validation efforts to 
improve upon scoring and confirm screening accuracy are 
needed to establish this tool as an aid in primary practice.
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